Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FLT3 Y842C||acute myeloid leukemia||resistant||Imatinib||Preclinical||Actionable||In a preclinical study, primary AML blasts expressing FLT3 Y842C were resistant to Gleevec (imatinib) as demonstrated by constitutively phosphorylated FLT3 and STAT-5 (PMID: 15345593).||15345593|
|FLT3 Y842C||acute myeloid leukemia||sensitive||FLT3 Inhibitor||Midostaurin||Preclinical - Cell culture||Actionable||In a preclinical study, Rydapt (midostaurin) induced cell death and inhibited FLT3 activation and downstream STAT5 activation in primary acute myeloid leukemic blasts harboring FLT3 Y842C in culture (PMID: 15345593).||15345593|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|